This trial collects blood, urine, and tissue samples to study the level of immune suppression in patients with pregnancy associated breast cancer (PABC) versus non-PABC, as well as comparing different types of breast cancer. The immune system is a complex network of cells that identifies our tissues as "self" or "foreign" as well as normal cells or cancer cells. When normal cells become cancer cells, they gain the ability to affect the body differently and knock down the immune system, a process known as immune suppression. This is part of what allows a cancer to grow and spread. Understanding the immune response and suppression in different types of breast cancer may help researchers better understand the mechanisms involved in breast cancer and may help the development of future treatments.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT01503190.
Locations matching your search criteria
United States
Colorado
Denver
University of ColoradoStatus: Active
Contact: Virginia F. Borges
Phone: 303-724-0186
PRIMARY OBJECTIVES:
I. Identify the presence of differing immune suppressive phenotypes in women with newly diagnosed breast cancer who fulfill the criteria of PABC (breast cancer diagnosed within 5-10 years of completed pregnancy) as compared to control cases (nulliparous or last pregnancy > 10 years ago).
Ia. Compare these cases to an additional control arm of women equal to or over the age of 46.
II. Identify the presence of differing immune suppressive phenotypes in women with newly diagnosed breast cancer as categorized by identified breast cancer biologic subtypes (luminal A, luminal B, Her 2 and triple negative/basal).
III. Confirm the presence of a pro-inflammatory stromal signature in PABC versus (v) controls prospectively in newly diagnosed cases in both primary breast cancers and their sites of metastasis.
IV. Demonstrate alterations in tumor: immune interactions in the tumor infiltrating lymphocytes and stroma of primary breast cancer and at site of metastasis in breast cancer defined by different breast cancer biologic subtype.
V. Identify the characteristics of young women’s breast cancer that are prognostic for disease recurrence, as stratified by breast cancer subtype and/or parity status at diagnosis and identify predictive markers of treatment outcomes as defined by circulating, immune and/or stromal: tumor microenvironment interactions.
OUTLINE:
Patients undergo collection of blood, urine, and tissue samples.
Trial PhasePhase O
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationUniversity of Colorado
Principal InvestigatorVirginia F. Borges